CPX2 Antibody

What experimental applications are validated for CPX2 antibodies in different model organisms?

CPX2 antibodies have been systematically characterized for Western blot (WB), immunohistochemistry (IHC), and immunofluorescence (IF/ICC) across species. Key validation data from peer-reviewed studies and commercial validations include:

Table 1: Validated CPX2 Antibody Applications

Methodological Recommendations:

• For WB: Use 2–20 µg/mL concentrations with recombinant protein controls to confirm target band size (e.g., 15 kDa for human CPX2) .

• For IHC: Optimize antigen retrieval using citrate buffer (pH 6.0) and validate with formalin-fixed paraffin-embedded neuronal tissues .

How does CPX2 regulate synaptic vesicle exocytosis at the molecular level?

CPX2 operates through dual regulatory mechanisms:

• Negative Regulation: Inhibits premature clustering of synaptic vesicles at presynaptic active zones by competing with synaptotagmin-1 for SNARE complex binding .

• Positive Regulation: Stabilizes primed vesicles during calcium-triggered exocytosis, ensuring synchronized neurotransmitter release. This is mediated through its N-terminal domain binding to the SNARE complex .

Experimental Validation:

• Use siRNA knockdown models to observe increased vesicle clustering (negative regulation) and impaired catecholamine secretion in chromaffin cells (positive regulation) .

What are the recommended controls for verifying CPX2 antibody specificity?

• Recombinant Protein Control: Include lanes with purified CPX2 (15 kDa) in WB to confirm target recognition .

• Knockout Validation: Compare staining in wild-type vs. Cplx2 / ⁻ tissues (e.g., spinal cord lysates from transgenic mice) .

• Pre-absorption Control: Incubate antibody with excess immunogen peptide (10x molar ratio) to abolish signal .

How to resolve discrepancies in CPX2 localization across neuronal subtypes?

Conflicting reports of CPX2 localization (presynaptic terminals vs. cytoplasmic pools) often arise from:

• Fixation Artifacts: Overfixation with paraformaldehyde (>4%) masks epitopes; optimize permeabilization with 0.1% Triton X-100 .

• Antibody Clonality: Polyclonal antibodies (e.g., ab232895) may detect isoforms with shared epitopes, while monoclonals (e.g., 100189) show subtype specificity .

Case Study:
In hippocampal neurons, polyclonal antibodies detect both soluble and membrane-bound CPX2 pools, whereas monoclonals localize exclusively to active zones due to epitope accessibility differences .

What strategies address cross-reactivity in non-model organisms?

For species without validated reactivity (e.g., zebrafish, Xenopus):

• Homology Analysis: Use Clustal Omega to align CPX2 sequences; >85% identity in the immunogen region predicts cross-reactivity .

• Empirical Testing: Screen antibody at 5–10 µg/mL in IF using CNS tissues, with knockout morphants as negative controls .

Table 2: Cross-Species Homology of CPX2 Epitopes

How to design isoform-specific CPX2 experiments?

CPX2 has splice variants (e.g., CPX2a/2b) with distinct C-terminal domains. To avoid cross-reactivity:

• Epitope Mapping: Use antibodies raised against isoform-unique regions (e.g., NovoPro’s monoclonal targets AA 50-134) .

• CRISPR-Cas9 Models: Generate cell lines with truncated CPX2 isoforms to test antibody specificity .

Data Interpretation Framework:

• If WB shows multiple bands, perform peptide competition assays to distinguish isoforms.

• Combine IF with in situ hybridization to correlate protein localization with isoform-specific mRNA distribution .

Case Example: Variable Subcellular Localization

• Conflict: Some studies report nuclear CPX2 in glioblastoma cells, contradicting synaptic localization.

• Resolution:

  • Test antibody cross-reactivity with CPXM2 (carboxypeptidase-like protein) using siRNA knockdown .

  • Validate findings with mass spectrometry of immunoprecipitated complexes .